European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Application of Cervista® human papilloma virus high-risk test in cervical cancer screening of Xinjiang Uyghur women
1 Department of Gynecology, the Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China
Eur. J. Gynaecol. Oncol. 2016, 37(4), 484–487; https://doi.org/10.12892/ejgo3107.2016
Published: 10 August 2016
Objective: This study aims to evaluate the diagnostic value of the Cervista® human papilloma virus (HPV) high-risk (HR) test in cervical cancer and precancerous lesion screening in Xinjiang Uyghur women. Materials and Methods: Three hundred and seventy three Uyghur women from Bachu County underwent the Cervista® HPV HR test, ThinPrep cytologic test, and cervical biopsy under a colposcope. Then the relationship between the infection rate of high-risk human papilloma virus (HR-HPV), the cytological results, and the histological results was analyzed. Results: With increasing cytological and pathological classification, the HR-HPV infection rate also increased and reached 100% in patients with cervical cancer. The highest proportion of the pathologically positive group consisted of patients with group A9 HPV infection as compared to patients infected with group A5/A6 or A7 HPV. Conclusion: HR-HPV is closely correlated with cervical cancer and precancerous lesions. Group A9 HPV has a high predictive value in cervical disease screening in Uyghur women. When cytological examination shows atypical squamous cells of undetermined significance (ASCUS), the Cervista® HPV HR test can provide a sensitive differentiation method.
Cervista HPV HR test
ThinPrep cytologic test